A phase 2b randomized trial to evaluate LYT-100 in patients with idiopathic pulmonary fibrosis (IPF)
P. Ford (London, United Kingdom), V. Cottin (Lyon, France), K. Flaherty (Ann Arbor, United States), T. Maher (Los Angeles, United States), P. Noble (Los Angeles, United States), M. Wijsenbeek (Rotterdam, Netherlands), M. Chen (Boston, United States), E. Elenko (Boston, United States), L. Micioni (Wall, United States), H. Paden (Woodbury, United States), M. Harnett (Boston, United States), J. Krop (Boston, United States)
Source: International Congress 2022 – Promising new approaches in idiopathic interstitial pneumonias
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Ford (London, United Kingdom), V. Cottin (Lyon, France), K. Flaherty (Ann Arbor, United States), T. Maher (Los Angeles, United States), P. Noble (Los Angeles, United States), M. Wijsenbeek (Rotterdam, Netherlands), M. Chen (Boston, United States), E. Elenko (Boston, United States), L. Micioni (Wall, United States), H. Paden (Woodbury, United States), M. Harnett (Boston, United States), J. Krop (Boston, United States). A phase 2b randomized trial to evaluate LYT-100 in patients with idiopathic pulmonary fibrosis (IPF). 1933
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|